transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?

Författare och institution:
G. M. Dallinga-Thie (-); J. Kroon (-); Jan Borén (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); M. J. Chapman (-)
Publicerad i:
Current Cardiology Reports, 18 ( 7 ) s. art no 67
ISSN:
1523-3782
Publikationstyp:
Artikel, refereegranskad vetenskaplig
Publiceringsår:
2016
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
It is now evident that elevated circulating levels of triglycerides in the non-fasting state, a marker for triglyceride (TG)-rich remnant particles, are associated with increased risk of premature cardiovascular disease (CVD). Recent findings from basic and clinical studies have begun to elucidate the mechanisms that contribute to the atherogenicity of these apoB-containing particles. Here, we review current knowledge of the formation, intravascular remodelling and catabolism of TG-rich lipoproteins and highlight (i) the pivotal players involved in this process, including lipoprotein lipase, glycosylphosphatidylinositol HDL binding protein 1 (GPIHBP1), apolipoprotein (apo) C-II, apoC-III, angiopoietin-like protein (ANGPTL) 3, 4 and 8, apoA-V and cholesteryl ester transfer protein; (ii) key determinants of triglyceride (TG) levels and notably rates of production of very-low-density lipoprotein 1 (VLDL1) particles; and (iii) the mechanisms which underlie the atherogenicity of remnant particles. Finally, we emphasise the polygenic nature of moderate hypertriglyceridemia and briefly discuss modalities for its clinical management. Several new therapeutic strategies to attenuate hypertriglyceridemia have appeared recently, among which those targeted to apoC-III appear to hold considerable promise.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin ->
Kardiologi
Nyckelord:
Triglycerides, Apolipoprotein, Heparin sulphate proteoglycan, apolipoprotein c-ii, angiopoietin-like protein, low-density-lipoprotein, proteoglycan-binding-site, coronary-artery-disease, ischemic-heart-disease, of-function mutations, nonfasting triglycerides, cardiovascular-disease, a-v
Postens nummer:
239460
Posten skapad:
2016-07-25 14:17
Posten ändrad:
2016-08-16 08:44

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007